We’re a clinical‑stage company pioneering tablet format peptide and protein replacement therapies that could redefine the standard of care for conditions with major unmet needs.
We’re a clinical‑stage company pioneering tablet format peptide and protein replacement therapies that could redefine the standard of care for conditions with major unmet needs.
Tablet Format Designed to Unlock Patient Acceptance and Drive Superior Health Outcomes
We leverage our N-Tab™ platform, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
EB613 (oral PTH(1-34)) is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34), teriparatide tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture.
Obesity, Metabolic Diseases and Short Bowel Disease Programs
We are developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases